Increased dose intensity of SGN-33, a humanized monoclonal antibody targeting CD33, is active and well-tolerated in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) Meeting Abstract
| Authors: | Raza, A.; Jurcic, J. G.; Roboz, G. J.; Stephenson, J. J.; Rarick, M. U.; Wood, B. L.; Grove, L. E.; Sieyers, E. L.; Drachman, J. G. |
| Abstract Title: | Increased dose intensity of SGN-33, a humanized monoclonal antibody targeting CD33, is active and well-tolerated in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) |
| Meeting Title: | 48th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 108 |
| Issue: | 11 Pt. 2 |
| Meeting Dates: | 2006 Dec 9-12 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2006-11-01 |
| Start Page: | 221B |
| End Page: | 222B |
| Language: | English |
| ACCESSION: | WOS:000242440401252 |
| PROVIDER: | wos |
| PUBMED: | 17139767 |
| DOI: | 10.1182/blood.V108.11.4568.4568 |
| Notes: | --- - Meeting Abstract: 4568 - 48th Annual Meeting of the American-Society-of-Hematology - DEC 09-12, 2006 - Orlando, FL - Part 2 - "Source: Wos" |
